{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:53:39Z","timestamp":1782816819525,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41391-025-00950-3","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:30:36Z","timestamp":1739975436000},"page":"908-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1784-7203","authenticated-orcid":false,"given":"Giulio","family":"Francolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Di Cataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Garlatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Aquilano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1068-5958","authenticated-orcid":false,"given":"Alessio","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4380-6947","authenticated-orcid":false,"given":"Gianluca","family":"Ingrosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando Maria","family":"D\u2019angelillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-0982","authenticated-orcid":false,"given":"Luca","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Augugliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Timon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Arcidiacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marvaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6106-7725","authenticated-orcid":false,"given":"Andrea","family":"Lancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simontacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Greto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Frosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Burchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Icro","family":"Meattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Valicenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"950_CR1","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41:5561\u20138.","journal-title":"J Clin Oncol"},{"key":"950_CR2","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl J Med. 2020;382:2091\u2013102.","journal-title":"N. Engl J Med"},{"key":"950_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration- resistant prostate cancer. N. Engl J Med. 2021;385:1091\u2013103.","journal-title":"N. Engl J Med"},{"key":"950_CR4","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, et al. Apalutamide in patients with metastatic castration- sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN Study. J Clin Oncol. 2021;39:2294\u2013303.","journal-title":"J Clin Oncol"},{"key":"950_CR5","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40:1616\u201322.","journal-title":"J Clin Oncol"},{"key":"950_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"950_CR7","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"950_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone- sensitive prostate cancer. N. Engl J Med. 2022;386:1132\u201342.","journal-title":"N. Engl J Med"},{"key":"950_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","volume":"185","author":"S Gillessen","year":"2023","unstructured":"Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer- metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023;185:178\u2013215.","journal-title":"Eur J Cancer"},{"key":"950_CR10","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/bjc.2017.103","volume":"116","author":"L Triggiani","year":"2017","unstructured":"Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017;116:1520\u20135.","journal-title":"Br J Cancer"},{"key":"950_CR11","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s00345-019-02717-7","volume":"37","author":"L Triggiani","year":"2019","unstructured":"Triggiani L, Mazzola R, Magrini SM, Ingrosso G, Borghetti P, Trippa F, et al. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol. 2019;37:2631\u20137.","journal-title":"World J Urol"},{"key":"950_CR12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s11547-022-01511-7","volume":"127","author":"G Francolini","year":"2022","unstructured":"Francolini G, Detti B, Di Cataldo V, Garlatti P, Aquilano M, Allegra A, et al. Study protocol and preliminary results from a mono- centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO- NCT03449719). Radiol Med. 2022;127:912\u20138.","journal-title":"Radiol Med"},{"key":"950_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","volume":"14","author":"PL Kellokumpu-Lehtinen","year":"2013","unstructured":"Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117\u201324.","journal-title":"Lancet Oncol"},{"key":"950_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl J Med. 2019;381:121\u201331.","journal-title":"N. Engl J Med"},{"key":"950_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02268-3","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Porreca A, Facchini G, Santini D, Bruni A, Simoni N, et al. PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative \u201ctriplet\u201d for oligometastatic hormone sensitive prostate cancer patients. Med Oncol. 2023;41:39. Published 2023 Dec 29.","journal-title":"Med Oncol"},{"key":"950_CR16","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108.","journal-title":"Lancet Oncol"},{"key":"950_CR17","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41:3339\u201351.","journal-title":"J Clin Oncol"},{"key":"950_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","volume":"84","author":"W Abida","year":"2023","unstructured":"Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, et al. Rucaparib for the Treatment of Metastatic Castration- resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023;84:321\u201330.","journal-title":"Eur Urol"},{"key":"950_CR19","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl J Med. 2020;383:2345\u201357.","journal-title":"N. Engl J Med"},{"key":"950_CR20","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40:3377\u201382.","journal-title":"J Clin Oncol"},{"key":"950_CR21","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, W\u00fclfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl J Med. 2019;381:2506\u201318.","journal-title":"N. Engl J Med"},{"key":"950_CR22","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20:1730\u20139.","journal-title":"Lancet Oncol"},{"key":"950_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","volume":"9","author":"C Tang","year":"2023","unstructured":"Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol. 2023;9:825\u201334.","journal-title":"JAMA Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00950-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T02:48:48Z","timestamp":1764038928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00950-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["950"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00950-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors decalare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Area Vasta Centro (approval no. 12855_spe, October 9, 2018). Informed consent was obtained from all individual participants included in the study. Every human participant provided an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}